T-Cell Lymphoma
The latest news, research, and perspectives in T-cell lymphoma. Most T-cell lymphomas are non-Hodgkin lymphomas that develop from mature T cells. The most common subtypes include mycosis fungoides, anaplastic large-cell lymphoma, and precursor T-lymphoblastic lymphoma.
Advertisement
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
The PETAL Consortium at the Jain Lab integrates AI-informed digital interface as a tool to facilitate clinical decisions.
Molecular analysis insights have improved clinical evaluation and management decision-making for the different PTCL subtypes.
A recent commentary makes recommendations to improve development and accelerated regulatory approval of novel agents.
A trial used consolidation after combination cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide.
Treatment with the monoclonal antibody 208 alone, and in combination with duvelisib, extended survival.
Advertisement
Subgroup analysis highlighted chemotherapy, disease type, and transplant factors associated with greater treatment efficacy.
Most grade 3 or worse adverse events had less occurrence in azacitidine therapy than in standard therapy.
Patients had higher tolerance of duvelisib when it was combined with romidepsin and greater treatment response.
Brigatinib showed promising responses in patients with ALK-positive anaplastic large-cell lymphoma after brentuximab vedotin.
Drs. Mehta-Shah and Horwitz comment on the lessons to be learned from the reanalysis of the Ro-CHOP trial.
Adding romidepsin to CHOP improved PFS in patients with peripheral T-cell lymphoma after long-term follow-up.
There were no significant differences in OS or PFS between allogeneic HSCT and autologous HSCT.
The NMPA approval for adult patients was based on the results from the multinational JACKPOT8 Part B study.
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
The US FDA has lifted the partial clinical hold on lacutamab following its analysis of a mortality in the TELLOMAK trial.
Enrollment paused in lacutamab cutaneous and peripheral T-cell lymphoma trials after unexpected severe adverse reaction.
Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
A first-in-human phase I trial will evaluate escalating doses of BITT2101 in patients with non-Hodgkin lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.